Developer of therapies designed to provide treatment of retinal diseases. The company's KSI 301 helps to restore vision and stop progression of underlying disease, enabling healthcare providers to cure their patients.
Pre-Clinical Trials
Publicly Held
Formerly VC-backed
The company raised $90 million in its initial public offering on the Nasdaq stock exchange under the ticker symbol of KOD on October 4, 2018. A total of 9,000,000 shares were sold at $10 per share. After the offering, there was a total of 36,573,353 outstanding shares at $10 per share, valuing the company at $365.73 million. The underwriters were granted an option to purchase up to an additional 1,350,000 shares from the company to cover over-allotments, if any.
Add a review